Ubiquitin and synaptic dysfunction: Ataxic mice highlight new common themes in neurological disease

Trends in Neurosciences

Volumn 26, Issue 1, 2003, Pages 4-7

  Ehlers, Michael D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; UBIQUITIN; UNCLASSIFIED DRUG; USP14 ENZYME;

ALZHEIMER DISEASE; ATAXIA; GENE IDENTIFICATION; GENETIC CODE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNAPSE; SYNAPTIC TRANSMISSION;

EID: 0037213155     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(02)00013-9     Document Type: Short Survey

References (34)

1. Walsh D.M., et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539.
2. Mesulam M.M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron. 24:1999;521-529.
3. Nalbantoglu J., et al. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 387:1997;500-505.
4. Chapman P.F., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2:1999;271-276.
5. Hsia A.Y., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad. Sci. U.S.A. 96:1999;3228-3233.
6. Mucke L., et al. High-level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:2000;4050-4058.
7. Fitzjohn S.M., et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J. Neurosci. 21:2001;4691-4698.
8. Barnes C.A. Normal aging: regionally specific changes in hippocampal synaptic transmission. Trends Neurosci. 17:1994;13-18.
9. 2+-dependent processes: relation to hippocampal synaptic plasticity. Hippocampus. 7:1997;602-612.
10. Foster T.C. Involvement of hippocampal synaptic plasticity in age-related memory decline. Brain Res. Brain Res. Rev. 30:1999;236-249.
11. Wilson S.M., et al. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat. Genet. 7:2002;7.
12. D'Amato C.J., Hicks S.P. Neuropathologic alterations in the ataxia (paralytic) mouse. Arch. Pathol. 80:1965;604-612.
13. Chung C.H., Baek S.H. Deubiquitinating enzymes: their diversity and emerging roles. Biochem. Biophys. Res. Commun. 266:1999;633-640.
14. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82:2002;373-428.
15. Hicke L. Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell Biol. 2:2001;195-201.
16. Wilkinson K.D. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J. 11:1997;1245-1256.
17. Yin L., et al. Nonhydrolyzable diubiquitin analogues are inhibitors of ubiquitin conjugation and deconjugation. Biochemistry. 39:2000;10001-10010.
18. Burt A.M. Morphologic abnormalities in the postnatal differentiation of CA1 pyramidal cells and granule cells in the hippocampal formation of the ataxic mouse. Anat. Rec. 196:1980;61-69.
19. Murphey R., Godenschwege T. New roles for ubiquitin in the assembly and function of neuronal circuits. Neuron. 36:2002;5.
20. Freir D.B., et al. Blockade of long-term potentiation by β-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J. Neurophysiol. 85:2001;708-713.
21. Kim J.H., et al. Use-dependent effects of amyloidogenic fragments of β-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J. Neurosci. 21:2001;1327-1333.
22. Stephan A., et al. Generation of aggregated β-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J. Neurosci. 21:2001;5703-5714.
23. Parent A., et al. Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol. Dis. 6:1999;56-62.
24. Zaman S.H., et al. Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine. Neurobiol. Dis. 7:2000;54-63.
25. Alves-Rodrigues A., et al. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci. 21:1998;516-520.
26. McNaught K.S., et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2:2001;589-594.
27. Jiang Y.H., et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron. 21:1998;799-811.
28. Moss A., et al. A role of the ubiquitin-proteasome system in neuropathic pain. J. Neurosci. 22:2002;1363-1372.
29. Fallon L., et al. Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J. Biol. Chem. 277:2002;486-491.
30. Zhang Y., et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. U.S.A. 97:2000;13354-13359.
31. van Leeuwen F.W., et al. Frameshift mutants of β amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science. 279:1998;242-247.
32. Lam Y.A., et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl Acad. Sci. USA. 97:2000;9902-9906.
33. Kim T.W., et al. Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J. Biol. Chem. 272:1997;11006-11010.
34. Steiner H., et al. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. 273:1998;32322-32331.